Paper PP20

Innovating Clinical Signal Surveillance: Real-Time Dashboards for Protocol and PK Deviation Monitoring

Rubina Pathan, Fortrea Development Pvt. Ltd, Bangalore, India
Jinu J Nair, Fortrea Development Pvt. Ltd, Bangalore, India

1. ABSTRACT

Timely detection of protocol deviations and pharmacokinetic (PK) sampling inconsistencies is vital for resilient clinical trial execution. Traditional monitoring methods relying on siloed data from Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), and Laboratory Information Management Systems (LIMS) create significant delays in identifying critical safety signals and compliance gaps. This technical paper presents a novel Real-Time Tableau Dashboard system developed by Fortrea that enables continuous monitoring, rapid detection, and interactive investigation of protocol deviations and PK sampling anomalies. The system integrates data from multiple sources including EDC, CTMS, LIMS, and safety databases (eRW) through a unified clinical data model, employing a four-step monitoring process for systematic issue identification. Our implementation demonstrates substantial improvements in operational efficiency: 80% reduction in issue identification time, 30% decrease in data review time, and 48-hour faster detection of safety signal emergence. The dashboard incorporates color-coded indicators, subject-level deviation tracking, and drill-down capabilities for root-cause analysis, enabling clinical research teams to proactively address quality issues before they impact patient safety or data integrity. This innovation represents a significant advancement in clinical trial surveillance methodology, supporting regulatory compliance requirements while reducing the burden of manual site monitoring.

2. INTRODUCTION

2.1 BACKGROUND

Clinical trials require continuous monitoring to ensure protocol compliance and accurate pharmacokinetic (PK) data collection. Traditional monitoring methods relying on static reports often delay the detection of protocol deviations and PK sampling inconsistencies, creating significant risks to patient safety, data integrity, and regulatory compliance. The pharmaceutical industry has long struggled with the challenge of synthesizing information from disparate data sources in a timely manner that enables proactive intervention.

Protocol deviations represent instances where study conduct diverges from the approved protocol, informed consent process, or regulatory requirements. These deviations can be major (significantly impacting participant safety, data integrity, or protocol compliance) or minor (procedural lapses with limited impact). The International Council for Harmonization (ICH) Good Clinical Practice (GCP) guidelines mandate that all deviations be documented, assessed for impact, and reported appropriately to sponsors and Institutional Review Boards (IRBs).

Pharmacokinetic sampling presents additional challenges, as accurate timing of blood sample collection is essential for reliable assessment of drug exposure parameters. Sampling time errors can introduce bias into pharmacokinetic parameter estimates, particularly when there is substantial curvature in the concentration-time profile around sampling points. Traditional methods of tracking PK sample timing against protocol windows require extensive manual verification, creating opportunities for delayed detection of systematic deviations.

2.2 INDUSTRY CHALLENGES

The current state of clinical trial monitoring faces several critical challenges.

- First, data exists in siloed systems including EDC, CTMS, safety databases, and laboratory systems, requiring manual reconciliation and synthesis.
- Second, static reporting approaches provide only retrospective views of trial status, limiting the ability to identify emerging issues in real-time. .
- Third, manual monitoring processes consume substantial resources while potentially missing time-critical deviations.

The FDA's 2013 guidance on risk-based monitoring advocated alternatives to traditional frequent onsite visits, recommending approaches that utilize critical data elements gathered in clinical data systems to identify risks to patient safety and determine which sites warrant additional attention. This regulatory shift has accelerated industry adoption of centralized monitoring approaches, yet many organizations still lack integrated visualization tools capable of synthesizing cross-functional data streams into actionable insights.

2.3 OBJECTIVES

The primary objective of this work was to develop a real-time dashboard solution that enables clinical research teams to detect protocol deviations and PK sampling inconsistencies with significantly reduced latency compared to traditional methods.

The specific goals included:

- integrating data from multiple clinical systems into a unified visualization platform.
- implementing automated alert mechanisms for critical deviations.
- providing interactive drill-down capabilities for root-cause analysis.
- and demonstrating measurable improvements in monitoring efficiency and detection speed.

3. SYSTEM ARCHITECTURE AND DATA FLOW

3.1 Unified Clinical Data Model

The system operates within the broader ecosystem of clinical trial technology platforms, interfacing with Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS), Laboratory Information Management Systems (LIMS), and safety databases. The innovation leverages Tableau as the visualization engine while introducing novel data integration patterns and analytical workflows specific to the challenges of clinical trial surveillance.

The foundation of the Real-Time Tableau Dashboard is a unified clinical data model that ingests data from multiple sources including EDC, CTMS, LIMS, and safety databases (eRW). This model enables seamless cross-functional analysis by establishing standardized data structures and relationship mappings across previously siloed systems.



Figure 1: System Architecture - Real-Time Tableau Dashboard for Protocol and PK Signals showing the four-layer data processing pipeline: (1) Data Sources consolidating site records, lab PK feeds, and subject event logs; (2) Processing Pipeline implementing real-time ETL, validation rules, and timing deviation calculations; (3) Tableau Dashboard providing interactive views, trends, subject-level deviations, and color-coded flags; (4) Investigation Tools enabling drill-down, filters, and case lists for rapid root-cause analysis.

3.2 Data Integration Layer

The data integration layer implements real-time Extract, Transform, Load (ETL) processes that continuously synchronize information from source systems. Key capabilities include automated data validation against protocol-defined rules; calculation of timing deviations for PK sampling events; standardization of coding dictionaries across sources; and maintenance of complete audit trails for regulatory compliance. The integration leverages API-based connections to cloud-hosted clinical systems, enabling near-real-time data availability.

The processing pipeline implements the following data flows: Site records including enrollment status, visit schedules, and protocol deviations are captured from CTMS; laboratory PK feeds providing sample collection times, analyte concentrations, and processing metadata are ingested from LIMS; subject event logs including adverse events, concomitant medications, and safety assessments are synchronized from EDC and safety databases. These streams are consolidated through a unified processing layer that applies validation rules and generates derived metrics for dashboard consumption.

3.3 Processing Pipeline Components

The processing pipeline consists of several specialized modules. The Timing Deviation Calculator compares actual PK sample collection times against protocol-specified nominal times, computing deviations in minutes and flagging samples outside acceptable windows. The Protocol Compliance Engine evaluates subject-level data against

inclusion/exclusion criteria, visit window requirements, and procedure completion mandates, generating deviation records for non-compliant events. The Safety Signal Aggregator monitors adverse event frequencies by body system organ class, computing statistical metrics to identify emerging safety concerns.

4. MONITORING WORKFLOW AND FEATURES

4.1 Four-Step Monitoring Process

The system employs a four-step monitoring process to improve data quality and timely intervention. This systematic approach enables clinical operations teams to maintain comprehensive oversight while prioritizing attention on the most critical issues.

Step 1 - PK Sample Timing: Detects early deviations from protocol window schedules. The system continuously monitors the time elapsed between drug administration and blood sample collection, comparing actual times against protocol-specified windows. Deviations are automatically flagged and categorized by severity, with systematic late draws warranting prompt investigation as potential indicators of site-level process issues.

Step 2 - Subject Level Checks: Flags emerging safety issues and protocol violations that require prompt attention. This component aggregates subject-level data across all collected domains, identifying patterns such as missed assessments, out-of-range laboratory values, and eligibility concerns. Subject profiles enable drill-down to individual-level detail for comprehensive case review.

Step 3 - Color-Coded Indicators: Implements a traffic light system using standardized color coding to indicate data status. Green indicates normal status with all parameters within acceptable ranges; yellow signals caution with parameters approaching thresholds or minor deviations noted; red indicates critical status requiring prompt action due to significant deviations or safety concerns. This visual prioritization system enables rapid triage during dashboard review sessions.

Step 4 - Interactive Drill-Down: Enables users to select data patterns and drill down to specific patient timelines for prompt context and detailed investigation. From aggregate views showing study-wide or site-level metrics, users can navigate individual subject profiles displaying complete event histories, treatment exposure, and deviation records. This capability supports efficient root-cause analysis and documentation of corrective actions.



Figure 2: Workflow

5. Dashboard Visualization Components

Tableau Dashboard incorporates several advanced technical capabilities that distinguish it from conventional clinical trial monitoring approaches:

Centralized Multi-Source Integration: Consolidated data from multiple clinical systems (EDC, CTMS, LIMS, eRW) into a single, unified analytical environment, eliminating the need for manual data reconciliation and enabling cross-domain analysis.

Real-Time Data Synchronization: Near-real-time data updates ensure that dashboard views reflect current study status, with configurable refresh intervals ranging from hourly to continuous streaming depending on source system capabilities.

Deviation Heatmaps: Visual representation of deviation patterns across multiple dimensions (sites, subjects, visits, timepoints) using color-intensity encoding to highlight magnitude and clustering of issues.

Automated Alerting: Configurable threshold-based alerts that proactively notify designated personnel when metrics exceed acceptable ranges, enabling rapid response to emerging issues.

5.1 Safety Signal Surveillance

The safety surveillance component enables continuous monitoring of adverse event profiles across the study population. with cell size indicating frequency and color indicating severity or recency. The system applies statistical methods to detect disproportionate reporting of specific events relative to background rates, enabling early identification of potential safety signals.

The Tableau Dashboard provides multiple interactive views tailored to different monitoring needs. The Protocol Compliance module tracks subject-level adherence to eligibility criteria, visit schedules, and procedural requirements. The Patient-Level Monitoring view provides longitudinal profiles for individual subjects, enabling detailed case review.

The dashboard consolidates deviation trends, site-level risk, and recent issues into a single view, enabling faster detection of compliance problems, focused site interventions, and improved trial oversight.



Figure 3: Comprehensive Overview Dashboard

This dashboard provides a real-time overview of protocol deviations across clinical trial sites to support proactive monitoring and corrective action.

Deviations by Category (Top Left): Displays the distribution of major and minor deviations across key categories such as Inclusion/Exclusion, Consent, Visit Schedule, IMP Compliance, Prohibited Medications, and PK/Labs. Visit Schedule and PK/Labs show the highest deviation counts, indicating common operational risk areas.

Site Performance: Deviations vs Enrollment (Top Right): Illustrates the relationship between the number of subjects enrolled at each site and total deviations. The dashed line represents an upper control limit, helping identify outlier sites with disproportionately high deviations relative to enrollment, which may require targeted review.

New & Changed Deviations (Bottom): A tabular view of recent deviations from the last 7 days, including site ID, subject, category, description, severity (major/minor), impact, and status (open/closed). This section enables rapid tracking, prioritization, and follow-up of active issues.

5.2 PK Sample Timing Analysis

The PK Sample Timing Deviations module displays heatmaps showing sampling compliance across study visits and subjects, with deviation magnitude indicated through color intensity. The Safety Signal Surveillance component presents adverse event frequency data organized with statistical alerts highlighting disproportionate reporting.

The pharmacokinetic sampling analysis module implements sophisticated timing deviation detection algorithms. For each PK sample, the system calculates the deviation between actual collection time and protocol-specified nominal time. The implementation recognizes that pharmacokinetic analysis requires complete data pairs (time, concentration) where concentration is dependent upon time, making accurate time recording essential for reliable parameter estimation.

The heatmap visualization displays subjects on the vertical axis and scheduled timepoints on the horizontal axis, with cell coloring indicating deviation magnitude. Green cells indicate on-time collection within acceptable windows; yellow indicates minor deviations; orange indicates moderate deviations requiring attention; and red indicates significant deviations that may impact data usability. This visual pattern enables rapid identification of systematic issues affecting specific timepoints or sites.



Figure 4: Real-Time Dashboards for Protocol and PK Deviation Monitoring - Interactive Tableau interface displaying, PK Sample Timing Deviations heatmap showing compliance patterns across subjects and timepoints.

6. BUSINESS IMPACT AND RESULTS

6.1 Quantitative Impact Metrics

Implementation of the Real-Time Tableau Dashboard has demonstrated substantial improvements in clinical trial monitoring efficiency. Key performance indicators measured across multiple study implementations include:

80% Faster Issue Identification: Automated deviation detection and visual highlighting enable monitors to identify high-risk sites or subjects significantly faster than manual review of tabular listings. The reduction in identification time

translates directly to earlier intervention and reduced impact of deviations on data quality.

30% Reduced Data Review Time: Interactive visualization of complex multi-domain data reduces the cognitive load associated with synthesizing information from disparate reports. Monitors can assess overall study health and drill down to specific concerns in a fraction of the time required for traditional review approaches.

48-Hour Faster Safety Signal Detection: The combination of real-time data integration and automated statistical surveillance enables detection of emerging safety signals approximately two days earlier than conventional periodic reporting would allow. This acceleration provides critical additional time for medical review and risk assessment.

6.2 Operational Benefits

Faster Resolution: Dramatically reduced time from deviation detection to corrective action implementation. The interactive investigation tools enable rapid root-cause identification, supporting efficient issue resolution workflows.

Enhanced Collaboration: Single source of truth for clinical and data management teams. Dashboard-based reviews facilitate aligned understanding of study status across functional groups, reducing miscommunication and duplicative analysis efforts.

Improved Data Quality: Higher quality data for clinical and regulatory submissions. Proactive identification and resolution of data issues throughout the study reduces the burden of retrospective data cleaning and minimizes the risk of late-stage quality findings.

Reduced Site Burden: Centralized monitoring capabilities reduce the frequency of onsite visits while maintaining comprehensive oversight, aligning with FDA risk-based monitoring guidance and reducing burden on clinical sites.

7. DISCUSSION

7.1 Comparison with Existing Approaches

The Real-Time Tableau Dashboard addresses limitations of existing clinical trial monitoring approaches in several key dimensions. Traditional static reporting methods, while valuable for regulatory submission, lack the interactivity needed to drill down into safety signals and explore subject-level data efficiently. Commercial solutions such as JReview and Spotfire dashboards offer dynamic visualizations but are typically packaged as add-ons to expensive clinical trial analytics environments.

The open architecture of our Tableau-based approach offers several advantages: source-agnostic data integration supporting connections to any EDC or clinical data system; configurable visualization components adaptable to study-specific requirements; and cost-effective deployment without requiring proprietary infrastructure. The implementation leverages Tableau's established position as an industry-standard business intelligence platform while introducing clinical-domain-specific analytical workflows.

7.2 Regulatory Alignment

The dashboard design aligns with evolving regulatory expectations for clinical trial oversight. The FDA's risk-based monitoring guidance emphasizes utilizing critical data elements to identify risks to patient safety and study data quality. The European Medicines Agency's Risk Management Plan requirements mandate systematic safety surveillance activities. Our implementation supports these requirements by providing comprehensive visibility into protocol compliance and safety signal trends.

7.3 Limitations and Future Directions

Current limitations include dependency on data availability and quality from source systems; the dashboard cannot identify issues that are not captured in integrated data streams. Additionally, while the visualization capabilities support rapid pattern recognition, interpretation of findings requires clinical and operational expertise that cannot be fully automated.

Future development directions include integration of machine learning algorithms for predictive analytics, enabling proactive identification of sites or subjects at elevated risk of future deviations based on early indicators. Natural language processing capabilities could extend surveillance to unstructured data sources such as site communications and narrative adverse event descriptions. Enhanced integration with electronic data capture workflows could enable real-time guidance to site personnel during data entry.

8. CONCLUSION

The Real-Time Tableau Dashboard successfully implements a transformational approach to clinical signal surveillance, enabling continuous monitoring of protocol deviations and pharmacokinetic data quality with demonstrated improvements in operational efficiency. The system's integration of data from multiple clinical sources, combined with interactive visualization capabilities and automated alerting, addresses longstanding challenges in clinical trial monitoring.

Key achievements include: 80% faster issue identification through automated detection and visual highlighting; 30% reduction in data review time through interactive multi-domain visualization; and 48-hour acceleration in safety signal detection through real-time data integration and statistical surveillance. These improvements translate directly to enhanced patient safety, improved data quality, and more efficient resource utilization.

The solution significantly enhances operational efficiency and data quality for regulatory submissions while reducing the burden of manual site monitoring. The source-agnostic architecture ensures compatibility with diverse clinical technology ecosystems, supporting broad applicability across therapeutic areas and study types. As the pharmaceutical industry continues to adopt risk-based monitoring approaches, real-time visualization and surveillance capabilities will become increasingly critical to maintaining trial integrity and protecting patient safety.

9. REFERENCES

1. U.S. Food and Drug Administration. (2013). Guidance for Industry: Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring. FDA.

2. International Council for Harmonisation. (2016). ICH E6(R2) Guideline for Good Clinical Practice. ICH.

3. Clinical Data Interchange Standards Consortium. (2021). Study Data Tabulation Model Implementation Guide. CDISC.

4. TransCelerate Biopharma Inc. (2023). Protocol Deviations: A Holistic Approach from Defining to Reporting. Journal of Clinical Trials.

5. Choi, L., et al. (2014). Practical recommendations for population PK studies with sampling time errors. Journal of Pharmacokinetics and Pharmacodynamics, 41(4), 355-367.

6. Zink, R.C., et al. (2018). The Safety Explorer Suite: Interactive Safety Monitoring for Clinical Trials. Therapeutic Innovation & Regulatory Science, 52(6), 696-700.

7. European Medicines Agency. (2017). Guideline on good pharmacovigilance practices - Module IX: Signal management. EMA.

8. Cramer, C.J., et al. (2019). Safety Monitoring in Clinical Trials. Pharmaceutical Statistics, 12(2), 105-113.

9. Rosenblum, D. (2024). Interactive medical and safety monitoring in clinical trials with clinDataReview. Frontiers in Medicine.

10. Tableau Software. (2025). Clinical Trial Data Visualization Best Practices. Tableau.

10. CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the author at:

Author Name: Rubina Pathan & Jinu J Nair
Company: Fortrea Development India Pvt. Ltd.
Address: Sattva Knowledge Court, 2nd Floor,
Wing B, Plot No. 9, Sy. No. 77, Doddenakkundi Phase I Industrial Area, Whitefield Road,
Mahadevapura, Bangalore, Karnataka, India – 560048
Email IDs: Rubina.Pathan@fortrea.com & JinuJanardhanan.Nair@fortrea.com
Website: www.fortrea.com